Education for NOAC Compliance not Beneficial -- or Needed

ACC Conference Reporter

ESC 2015 | LONDON — Assigning patients with atrial fibrillation to a special class on the need for compliance in taking the anticoagulant apixaban (Eliquis) did not seem to increase the adherence level beyond the very high rate seen with usual care – at least for the first 6 months of therapy, researchers reported here. Read More >>>

Keywords: ESC Congress

< Back to Listings